Avanos Medical (AVNS) Cash from Financing Activities (2013 - 2026)

Avanos Medical has disclosed Cash from Financing Activities across 14 years of filings, most recently posting -$3.2 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$3.2 million, up 89.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$11.1 million (up 85.68% YoY), and the FY2025 annual result was -$37.0 million, up 24.64% from the prior year.
• Cash from Financing Activities came in at -$3.2 million for Q1 2026 at Avanos Medical, down from -$2.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $105.7 million in Q1 2022 to a low of -$114.7 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$5.0 million (2024), against an average of -$7.5 million.
• Across the five-year window, Cash from Financing Activities surged 52950.0% in 2022 and sank 4057.14% in 2025, its largest moves.
• Avanos Medical's Cash from Financing Activities stood at -$21.9 million in 2022, then slumped by 423.74% to -$114.7 million in 2023, then jumped by 76.11% to -$27.4 million in 2024, then surged by 90.15% to -$2.7 million in 2025, then retreated by 18.52% to -$3.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$3.2 million (Q1 2026), -$2.7 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.